Atlas Trials

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

Clinical trial NCT04560569 · UNKNOWN

Trial details

NCT number
NCT04560569
Sponsor
Frontier Biotechnologies Inc.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
HIV/AIDS
Start date
2021-11-30
Primary completion
2022-11-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.